Federal Policy for Lowering Prescription Drug Prices
Journal of Science Policy & Governance · 2020
DOI: 10.38126/jspg170110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Science Policy & Governance, 2020. Verfasst von Amanda Hurley und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Both Republicans and Democrats are determined to lower the escalating cost of prescription drug prices, which is projected to reach $605 billion/yr by 2026 (Committee on Ways and Means 2019). In this memorandum, we explore the possible outcomes of, 1) linking U.S. drug prices to the international median incentivized by re-importation of the U.S.-made drugs from other countries, 2) allowing the Secretary of Health and Human Services (HHS) to negotiate Medicare part D drugs incentivized through patent exemption and, 3) funding drug discovery through prizes instead of market-exclusive patents. We recommend that the next presidential candidate approve Option 2 and advocate for HHS Secretary negotiation powers with patent exemptions for non-compliant companies.
Zitieren
APA
Hurley, A., Sheftel, C. M., & Canales, A. (2020). Federal Policy for Lowering Prescription Drug Prices. Journal of Science Policy & Governance. https://doi.org/10.38126/jspg170110
Vancouver
Hurley A, Sheftel CM, Canales A. Federal Policy for Lowering Prescription Drug Prices. Journal of Science Policy & Governance. 2020. doi:10.38126/jspg170110
BibTeX
@article{Hurley2020,
author = {Hurley, Amanda and Sheftel, Celeste M. and Canales, Alejandra},
title = {Federal Policy for Lowering Prescription Drug Prices},
journal = {Journal of Science Policy & Governance},
year = {2020},
doi = {10.38126/jspg170110}
}
EUVIMED